ADP-ribosylation (ADPRylation) is a post-translational modification of proteins catalyzed by
ADP-ribosyl transferase (ART) enzymes, including nuclear PARPs (eg, PARP1 and PARP2) …

Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor
genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and …

Poly (ADP-ribose) polymerase-1 (PARP1) has been reported to play an important role in
longevity. Here, we showed that the knockdown of the PARP1 extended the lifespan of …

Within the growing field of amino acid metabolism, tryptophan (Trp) catabolism is an area of
increasing interest. Trp is essential for protein synthesis, and its metabolism gives rise to …

Poly (ADP) ribosylation inhibitors (PARPis) are toxic to cancer cells with homologous
recombination (HR) deficiency but not to HR-proficient cells in the tumor microenvironment …

Increasing evidence suggests synaptic dysfunction is a central and possibly triggering factor
in Amyotrophic Lateral Sclerosis (ALS). Despite this, we still know very little about the …

Breast cancer is a heterogeneous disorder with different molecular subtypes and biological
characteristics for which there are diverse therapeutic approaches and clinical outcomes …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) resistance remains a
therapeutic challenge in ovarian cancer. High-mobility group box 3 (HMGB3) plays …

The PARP inhibitor (PARPi) olaparib is currently the drug of choice for serous ovarian
cancer (OC), especially in patients with homologous recombination (HR) repair deficiency …

Targeting poly (ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the
treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation …